Quintiles Transnational Holdings Inc. (NYSE:Q)

Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina.

Quintiles Transnational Holdings Inc. (NYSE:Q)’s Financial Overview

Quintiles Transnational Holdings Inc. (NYSE:Q) declined -5.07% yesterday to close its trading session at $76.83. The company has 1 year Price Target of $83.44. Quintiles Transnational Holdings Inc. has 52-Week high of $81.45 and 52-Week Low of $55.01. The stock touched its 52-Week High on Oct 5, 2016 and 52-Week Low on Feb 9, 2016. The stock traded with the volume of 4.81 Million shares yesterday. The firm shows the market capitalization of $18.91 Billion.

Quintiles Transnational Holdings Inc. (NYSE:Q) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $1/share against the analyst consensus estimate of $0.99/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 1%.

The firm is trading with SMA20 of -0.57 Percent, SMA50 of -0.27 Percent and SMA200 of 7.65 percent. Quintiles Transnational Holdings Inc. has P/S value of 3.12 while its P/B value stands at 0. Similarly, the company has Return on Assets of 9.9 percent, Return on Equity of -89.7 percent and Return on Investment of 25.2 Percent. The company shows Gross Margin and Operating Margin of 28 percent and 11.1 percent respectively.

Many brokerage firms are involved in issuing their ratings on Quintiles Transnational Holdings Inc. (NYSE:Q). On 27-Oct-16 Piper Jaffray Downgrade Quintiles Transnational Holdings Inc. Stock  to Neutral. Another firm also rated the stock on 19-Oct-16 where Jefferies Downgrade the stock to Hold.

The Stock currently has Analyst’ mean Recommendation of 2.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 16 analysts offering 12-month price forecasts for Quintiles IMS Holdings Inc have a median target of 85.00, with a high estimate of 94.00 and a low estimate of 72.00. The median estimate represents a +10.63% increase from the last price of 76.83.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Synthetic Biologics Inc. (NYSEMKT:SYN)

Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan.

Synthetic Biologics Inc. (NYSEMKT:SYN)’s Financial Outlook

The 5 analysts offering 12-month price forecasts for Synthetic Biologics Inc have a median target of 5.75, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a +621.64% increase from the last price of 0.80.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Synthetic Biologics Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -5.42% and closed its last trading session at $0.8. The company has the market capitalization of $92.96 Million. The stock has 52-week high of $3 and 52-Week low of $0.77. The firm touched its 52-Week high on Dec 2, 2015 and 52-Week low on Nov 23, 2016. The company has volume of 2.01 Million shares. The company has a total of 116.67 Million shares outstanding.

Synthetic Biologics Inc. (NYSEMKT:SYN) in the last quarter reported its actual EPS of $-0.09/share where the analyst estimated EPS was $-0.1/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 10 percent.

The company has YTD performance of -65.21 percent. Beta for Synthetic Biologics Inc. stands at 1.46 while its ATR (average true range) is 0.11. The company has Weekly Volatility of 6.80%% and Monthly Volatility of 9.07%%.

Synthetic Biologics Inc. has distance from 20-day Simple Moving Average (SMA20) of -28.67%, Distance from 50-Day Simple Moving Average of -44.39 percent and Distance from 200-Day Simple Moving Average of -55.8%.

The Company currently has ROA (Return on Assets) of -183.5 percent, Return on Equity (ROE) of -712.7 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.